The signal is tied to bacterial metabolic activity: lux-encoded bacterial luciferase and its associated enzymes generate light when the engineered mycobacteria remain metabolically active. This provides a functional readout of viable organisms rather than merely indicating that mycobacterial material is present. In infection studies, emitted luminescence can support estimation of changes in living bacterial burden over time.
The lux genes encode bacterial luciferase together with associated enzymes needed for light generation. Their coordinated activity converts ongoing cellular metabolism into an observable luminescent signal. Because the signal depends on the engineered bacterium’s metabolic state, researchers can use it to track viable mycobacteria during experimental infection rather than relying only on a static measurement.
Noninvasive luminescence allows researchers to monitor infection without repeatedly disrupting the experimental model to assess bacterial survival. Repeated observations can reveal how the bacterial population changes over time, including increases, decreases, or continued persistence. This time-resolved approach is especially useful when evaluating interactions between mycobacteria and host immune defenses.
Researchers measure emitted luminescence at successive time points and use changes in the signal to assess bacterial burden in the experimental model. This supports real-time observation of infection dynamics rather than a single endpoint assessment. The resulting measurements can show whether viable mycobacteria are being reduced, maintained, or increasing during the study.
Tracking luminescence over time can provide information about where infection-related bacterial activity is detected and whether it continues after the initial phase. Patterns of signal change can therefore support assessment of dissemination and persistence in experimental models. This longitudinal information helps researchers examine the progression of mycobacterial infection under changing host or treatment conditions.
BCG-Lux enables researchers to compare luminescent signals during antimicrobial exposure or immune challenge. A changing signal can indicate altered survival of viable mycobacteria as treatment or host defenses act on the infection. In immunology and infection studies, this supports real-time assessment of bacterial responses and helps relate immune activity or antimicrobial treatment to infection outcomes.